Geron is also busy looking into additional hematological indications for imetelstat. My take is that management wants to make imetelstat a one-stop shop for hematological malignancies in order to give it multiple potential routes to blockbuster status.
Even so, I think management's ultimate goal is to make Geron an attractive buyout target. While it's certainly easy to draw comparisons to Gilead Sciences buyout of YM Biosciences for its mid-stage myelofibrosis drug, Foolish investors would be wise to look into Scarlett's track record as a CEO.
Basically, Scarlett is famous for selling his companies to the highest bidder. In short, I think Geron is a strong buyout candidate going forward, especially if imetelstat continues to show promise as a treatment for myelofibrosis.
Adam Feuerstein is Crammers Butt Buddy !
Adam Feuerstein like Crammer should be investigated by the SEC and FEDS for the lying they do for their pals on Wall street, this company has a proven cure and is a buy no matter what you hear study the facts on your own,
patience is the key. If you are like me, you watch, with a steady eye, your watchlist. Then, out of your list, some...one stock...begins to become energized. So, you wait and watch the price jump around. Level II begins moving quickly... then you jump on it. This is what will happen to GERON. I promise. You just have to wait and be patient. Too many good things are on the horizon.
interesting comments -any opinion on timing for a sale and price point CEO will be looking for, based on past track record -I'm not familiar with the CEO's past escapades...thanks in advance for any additional comments....